Sofie, Lantheus ink deal for prostate cancer imaging agent

By staff writers

November 13, 2020 -- Molecular imaging developer Sofie Biosciences has signed a commercial supply agreement with Lantheus Holdings, parent company of Lantheus Medical Imaging, to manufacture and distribute Lantheus' lead investigational prostate cancer imaging agent, PyL (F-18 DCFPYL).

Following U.S. Food and Drug Administration (FDA) approval of the agent, Sofie will roll out PyL via its national network. The firm has already manufactured 500 doses of PyL during clinical trials and will be able to meet the expected commercial demand for the imaging agent, Sofie said.

Copyright © 2020
Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking